Further studies are warranted to assess the potential use of NGR-TNF (or its more stable and homogeneous derivative S-NGR-TNF), in combination with chemo/immunotherapy, for the treatment of other primary and secondary brain tumors, such as glioblastoma multiforme and brain metastases of breast and lung cancer. This evidence concerns the gene RTN4R and glioblastoma.